ArticleBMC pulmonary medicine2026
Role of cell-free DNA technology in assisting paraffin-embedded cytology for the pathological diagnosis of pulmonary tuberculosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePulmonary tuberculosis (PTB) remains a significant global health problem in the 21st century. This study explored the diagnostic value of cell-free DNA (cfDNA) technology-assisted acid-fast staining (AFS) for PTB.
methodsA retrospective analysis was conducted on 237 suspected PTB patients. All sectioned specimens underwent AFS, and plasma samples were tested for cfDNA. Patients were categorized into positive and negative groups based on etiology and clinical symptom reference standards. The diagnostic value of cfDNA-assisted AFS was analyzed using receiver operating characteristic (ROC) curves. The concordance rates of cfDNA and AFS were calculated based on true-positive and true-negative cases, and their consistency was assessed using the Kappa test.
resultsUnder the etiological and clinical reference standards, the true-positive detection rate for PTB of cfDNA was higher than that of AFS (79.05% vs. 65.87% and 68.72% vs. 55.38%, respectively). cfDNA-assisted AFS exhibited superior diagnostic performance over either test alone, yielding higher AUCs (0.946 vs. 0.808 for AFS and 0.874 for cfDNA under etiological reference standard; 0.853 vs. 0.717 for AFS and 0.832 for cfDNA under clinical reference standard). Similarly, the combined approach significantly enhanced sensitivity (96.41% and 82.56%) and specificity (92.86% and 88.10%). cfDNA-assisted AFS showed higher Kappa values than either AFS or cfDNA alone under both reference standards (etiology: κ = 0.889 vs. κ = 0.503 vs. κ = 0.662; clinical symptom: κ = 0.556 vs. κ = 0.246 vs. κ = 0.425).
conclusionCfDNA-assisted AFS enhances the diagnostic performance for PTB, providing a novel auxiliary tool for the clinical diagnosis of PTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.